Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
390 CHF | -0.76% |
|
-2.74% | +28.71% |
11:37am | Ypsomed Partner Secures US FDA Nod for Automated Insulin Delivery Algorithm | MT |
12/06 | German Pharmaceutical Medac Picks Ypsomed Autoinjector for Methotrexate Pen Relaunch | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- With an expected P/E ratio at 46.34 and 30.52 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+28.71% | 606.7Cr | B- | ||
-3.19% | 10TCr | C | ||
-4.14% | 6.75TCr | A | ||
+15.49% | 4.67TCr | B- | ||
-6.00% | 4.64TCr | B- | ||
+4.82% | 4.09TCr | B+ | ||
+22.10% | 3.16TCr | B | ||
+12.18% | 2.43TCr | A- | ||
-8.53% | 2.35TCr | A- | ||
-12.33% | 2.19TCr | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- YPSN Stock
- Ratings Ypsomed Holding AG